AtCor's pressure rises
Wednesday, 30 July, 2008
AtCor Medical Holdings [ASX: ACG] has recorded its best sales figures ever, totalling around $6.5 million in 2008.
This represents a 47 per cent increase over last year's sales.
The largest gain was in Europe, where sales increased by 59 per cent. In North America sales increased by 46 per cent, and rest of the world by eight per cent.
The company's main product, the SphygmoCor system, identifies the effects of reflected blood pressure in the central aortic pressure wave.
Last week, the company reported two contracts for a total of US$1.6 million for pharmaceutical company.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
